All articles tagged with #boulevard bio
Boulevard Bio, co-founded by renowned autoimmune researcher Georg Schett, signals a shift toward antibody therapies and away from CAR-T, marking Schett’s first co-foundership as he continues to advise several biotech startups.
Boulevard Bio surfaced from stealth with $65 million in funding from Deerfield Management to advance three autoimmune drug candidates. Led by Mahesh Karande and co-founded with Georg Schett, the company’s lead asset BLVD101 is a bispecific BAFF/APRIL antibody for IgA nephropathy (IgAN) with a 12-week dosing schedule and favorable interim Phase 1 safety data. The portfolio also includes BLVD201, a trispecific CD19/BCMA/CD3 T-cell engager licensed from METiS Techbio, and BLVD301 in IND-enabling stages, underpinned by 3DC’s B-cell–focused platform and Metis’ NanoForge technology. Boulevard emphasizes multi-target, patient-centric approaches to address B-cell–driven autoimmune diseases.